Sign Up to like & get recommendations! 1
Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.25438
Abstract: Key Points Question What are the factors associated with pregnancy-related attacks in neuromyelitis optica spectrum disorder? Findings This systematic review and meta-analysis of 15 studies with 443 patients found that receiving immunosuppressive treatment during pregnancy… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Annals of Clinical and Translational Neurology"
DOI: 10.1002/acn3.51683
Abstract: Our study aimed to investigate the influence of pregnancy on the course of neuromyelitis optica spectrum disorders (NMOSD) and to explore the independent predictors of pregnancy‐related attacks. read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Annals of Neurology"
DOI: 10.1002/ana.26067
Abstract: Blood tests to monitor disease activity, attack severity, or treatment impact in neuromyelitis optica spectrum disorder (NMOSD) have not been developed. This study investigated the relationship between serum glial fibrillary acidic protein (sGFAP) concentration and… read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "Annals of Neurology"
DOI: 10.1002/ana.26623
Abstract: To investigate aquaporin‐4 antibody (AQP4‐IgG) dynamics and relapse risk in patients with seropositive neuromyelitis optica spectrum disorder treated with immunosuppressants. read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "Annals of Neurology"
DOI: 10.1002/ana.26626
Abstract: CHAMPION‐NMOSD (NCT04201262) is a phase 3, open‐label, externally controlled interventional study evaluating the efficacy and safety of the terminal complement inhibitor ravulizumab in adult patients with anti–aquaporin‐4 antibody–positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD). Ravulizumab… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Brain and Behavior"
DOI: 10.1002/brb3.584
Abstract: Previous studies have shown that serum uric acid (UA) modulates outcomes of neurological diseases, although little is known about cerebrospinal fluid (CSF) UA levels in neuromyelitis optica spectrum disorders (NMOSDs). read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Glia"
DOI: 10.1002/glia.24271
Abstract: Neuromyelitis optica spectrum disorder (NMOSD) is a severe inflammatory autoimmune disease of the central nervous system that is manifested as secondary myelin loss. Oligodendrocyte progenitor cells (OPCs) are the principal source of myelinating oligodendrocytes (OLs)… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Journal of Magnetic Resonance Imaging"
DOI: 10.1002/jmri.25866
Abstract: Multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) are central nervous system (CNS) inflammatory demyelinating disorders. It is clinically important to distinguish MS from NMOSD, as treatment and prognosis differ. Brainstem involvement is common… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Journal of Magnetic Resonance Imaging"
DOI: 10.1002/jmri.26287
Abstract: Precise diagnosis and early appropriate treatment are of importance to reduce neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) morbidity. Distinguishing NMOSD from MS based on clinical manifestations and neuroimaging remains challenging. read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Der Nervenarzt"
DOI: 10.1007/s00115-018-0486-4
Abstract: BACKGROUND Neuromyelitis optica spectrum disorders (NMOSD) are autoimmune inflammatory diseases of the central nervous system that mainly affect women. In some of these patients NMOSD occurs during fertile age. For this reason, treating physicians may… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Der Nervenarzt"
DOI: 10.1007/s00115-021-01098-w
Abstract: Neuromyelitis optica spectrum disorder (NMOSD), derived from NMO or Devic's disease, is considered as a distinct disease since the discovery of a novel and pathogenic serum autoantibody targeting aquaporin‑4 (AQP4-IgG) and is distinguished from classical multiple sclerosis… read more here.